Live Chat Software
August 13, 2020 • 12:00 PM - 2:30 PM ET
The Centers for Disease Control and Prevention’s recent report that patients with an underlying medical condition were 6-times more likely to be hospitalized, and 12-times more likely to die from COVID-19, confirmed what the health care industry has known for decades: we as health care leaders must continue the difficult work of improving patients’ medication therapy adherence, persistence, and compliance, and chronic condition management to improve the health of the populations we serve. During this four-part webinar, learn from several leaders around the globe from the Upjohn Division of Pfizer Inc, who are using real-world data (RWD) and evidence (RWE) to develop best practices and work collaboratively with health care stakeholders to make a positive impact on this decades-old challenge.
Webinar Agenda:
12:00 – 12:35 pm
PART 1: Realize the Burden of Comorbidities – How the Pandemic Underscored the Importance of Chronic Condition Management and Adherence
The link between communicable and noncommunicable diseases (NCDs) was clearly highlighted in the recent pandemic. Adults with advanced age and NCDs were more prone to have a severe form of Covid-19. Optimal adherence to chronic medications and interventions plays a critical role in improving therapeutic outcomes during the pandemic.
The link between communicable and noncommunicable diseases (NCDs) was clearly highlighted in the recent pandemic. Adults with advanced age and NCDs were more prone to have a severe form of Covid-19. Optimal adherence to chronic medications and interventions plays a critical role in improving therapeutic outcomes during the pandemic.
- Understand the relationship between Covid-19 and NCDs like cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes
- Examine data from the US, Europe, and China showing this link
- Learn how to evaluate, interpret, and depict patient data to better inform about medication adherence and persistence
|
|
Tarek Hassan, MD Senior Medical Director & Global Therapy Area Lead, Upjohn Division Pfizer View Bio |
12:35 – 1:10 pm
PART 2: Learnings from the Adherence Center of Excellence (COE) and Strategies in Developed Markets
Gain insights learned through the collaboration of global leaders in developed markets as well as advocacy groups to better understand the impact of non-adherence on patients´ health outcomes as well as on the sustainability of health systems.
Gain insights learned through the collaboration of global leaders in developed markets as well as advocacy groups to better understand the impact of non-adherence on patients´ health outcomes as well as on the sustainability of health systems.
- Learn how optimal achievement of appropriate levels of adherence require tailored, multi-faceted interventions
- Examine the multi-dimensional factors associated with non-adherence, particularly those related to patients’ education and their information needs
- Learn how the Adherence COE focus on Research and Education on Adherence allows us to better understand and address the reasons why patients do not take their medications as prescribed (non-adherence) based on proven experiences of doctors and researchers from around the globe
|
|
Danute Ducinskiene, MD, PhD Medical Lead, East Alliance, Developed Markets, R&D; and Medical, Upjohn Division Pfizer Inc View Bio |
|
|
Jorge Enrique Sáenz, MD Spain and East Alliance Markets Medical Lead, Developed Markets, R&D; and Medical, Upjohn Division Pfizer Inc View Bio |
1:10 – 1:45 pm
PART 3: Use Statistical Outcomes Research Methods, Patient Journey Mapping, and Insights on Medication Switches to Inform Your Adherence Strategy
A wealth of insights can be garnered through RWD to inform your patient adherence, persistence, and compliance strategy. Map the patient journey to better understand why and where patients have non- or low adherence of medications.
A wealth of insights can be garnered through RWD to inform your patient adherence, persistence, and compliance strategy. Map the patient journey to better understand why and where patients have non- or low adherence of medications.
- Review the concepts of and the statistical methodology for measuring adherence and compliance
- Examine the various ways to visualize and map the patient journey where adherence plays an important role in patients' disease prognosis and disease management
- Exemplify observational study designs to harness real world data to gain RWE in measuring adherence
|
Kelly H. Zou, PhD, PStat®, FASA Vice President, Head of Medical Analytics and Insights, Medical Analytics and Insights, R&D; and Medical, Upjohn Division Pfizer Inc View Bio |
Kelly H. Zou
|
|
Kelly H. Zou, PhD, PStat®, FASA
Vice President, Head of Medical Analytics and Insights, Medical Analytics and Insights, R&D; and Medical, Upjohn Division Pfizer Inc |
Kelly Zou, Ph.D., PStat®, FASA is Vice President, Head of Medical Analytics & Insights, R&D; and Medical, Upjohn Division, Pfizer Inc. She is an elected Fellow of the American Statistical Association and an Accredited Professional Statistician. Previously, she was Senior Director, Global Real World Evidence Center of Excellence and Senior Director, Statistical Center for Outcomes, Real World & Aggregate Data at Pfizer. She was Associate Professor at Harvard Medical School, as well as Director of Biostatistics at its affiliated teaching hospitals. She was Associate Director of Rates at Barclays Capital. She received both MA and PhD degrees in Statistics from the University of Rochester, following a BA in Mathematics (Summa Cum Laude), with a Minor in Physics. She completed her Postdoctoral Fellowship at Harvard. Her research interests include health policy, real world evidence, signal detection, and artificial intelligence, with over 140 professional articles and 4 books. She was featured as an Outstanding Woman in Data Analytics by Forbes, an Inspirational Women in Statistics & Data Science by Wiley and the Royal Statistical Society, and an Accomplished Woman in Statistics and Data Science by the American Statistical Association.
1:45 – 2:30 pm
PART 4: How Regulatory and Policy Advancements and Innovations in Access, Telehealth, and Digital Strategies Can Improve Adherence
While the focus is growing on improving health care, so too, are real world data and the evidence drawn from it. What is the relevance and what are the uses of RWE today? Who is using it and how is its use changing patient access?
While the focus is growing on improving health care, so too, are real world data and the evidence drawn from it. What is the relevance and what are the uses of RWE today? Who is using it and how is its use changing patient access?
- Examine mHealth as a means of harnessing RWD and leveraging RWE to help improve outcomes
- Consider the case of adherence and how it can be affected by telemedicine
- With COVID-19, explore how access is changing and the role mHealth can play in increasing access and adherence
- Discuss the application of Digital Technology in enhancing the delivery of standard Adherence measurement statistics
- Leverage the advances in technology and the expanding availability of RWD
- Identify opportunities that now exist to provide dynamic insights into patient adherence on a product and market level in an easy to consume and access format, via applications like an "Adherence Dashboard"
|
|
Joseph P. Cook, PhD, JD Senior Director, Population Health Lead, Medical Analytics and Insights, R&D; and Medical, Upjohn Division Pfizer Inc View Bio |
|
|
Joseph Imperato, MS, ME Senior Director, Real World Data and Evidence Lead, Medical Analytics and Insights, Business Technology, Upjohn Division Pfizer Inc View Bio |